Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1

Bibliographic Details
Main Authors:	Coates, L, Kishimoto, M, Gottlieb, A, Shuler, C, Lin, C, Lee, C, Mease, P
Format:	Journal article
Language:	English
Published:	BMJ Publishing Group 2017

Effect of concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) on the efficacy and safety of ixekizumab in biologic dmard-naive patients with active psoriatic arthritis
by: Coates, LC, et al.
Published: (2016)

Non tropical pharmacological treatment of early, untreated (Dmard-Naïve) psoriatic disease: A systematic review
by: De Marco, G, et al.
Published: (2019)

A SURVEY OF DMARD PREFERENCES OF UK RHEUMATOLOGISTS
by: Douglas, K, et al.
Published: (2003)

Myocardial infarction in rheumatoid arthritis: The effects of DMARDs and prednisolone
by: Edwards, C, et al.
Published: (2008)

Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope
by: Tillett, W, et al.
Published: (2020)

A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis.
by: Jobanputra, P, et al.
Published: (2004)

Combination therapy with DMARDs and biological agents in collagen-induced arthritis.
by: Williams, R, et al.
Published: (1999)

Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs
by: Tucker, L, et al.
Published: (2022)

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase 3, randomised, placebo controlled, active reference BE OPTIMAL study
by: Ritchlin, CT, et al.
Published: (2023)

Individual DMARDs have different effects on the likelihood of developing septic arthritis in adults with rheumatoid arthritis
by: Edwards, C, et al.
Published: (2005)

To stop or not to stop: what should we be doing with biologic DMARDs when patients undergo orthopaedic surgery?
by: van Duren, BH, et al.
Published: (2021)

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
by: Coates, LC, et al.
Published: (2022)

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
by: Coates, L, et al.
Published: (2022)

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients
by: Humby, F, et al.
Published: (2019)

Incidence of hip and knee replacement in patients with rheumatoid arthritis following the introduction of biological DMARDs: an interrupted time-series analysis using nationwide Danish healthcare registers
by: Cordtz, R, et al.
Published: (2017)

Incidence of knee and hip replacements in rheumatoid arthritis patients following introduction of biological dmards: an interrupted time series analysis using nationwide health care registers
by: Cordtz, R, et al.
Published: (2017)

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
by: Coates, LC, et al.
Published: (2022)

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)
by: Mease, P, et al.
Published: (2018)

24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: Taylor, P, et al.
Published: (2013)

Long-term efficacy of baricitinib in patients with rheumatoid arthritis who have had inadequate response to csDMARDs: results from ra-beyond up to 7 years of treatment
by: Caporali, R, et al.
Published: (2022)

Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC
by: Coates, LC, et al.
Published: (2021)

The protocol of a clinical effectiveness trial comparing standard step-up care, early combination DMARD therapy and early use of TNF inhibitors for the treatment of moderate to severe psoriatic arthritis: the 3-arm parallel group SPEED randomized controlled trial
by: Watson, M, et al.
Published: (2024)

Comparative effectiveness of tumour necrosis factor inhibitor therapy vs. conventional synthetic dmards on need for joint replacement among rheumatoid arthritis patients: A propensity score matched analysis of UK registry data
by: Hawley, S, et al.
Published: (2018)

Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PSA-1 and SELECT-PsA-2 trials assessed according to modified PsARC
by: Coates, LC, et al.
Published: (2022)

Changes in incidence of shoulder, elbow, wrist and finger replacement surgery among rheumatoid arthritis patients following the introduction of biological dmards: an interrupted time series analysis using danish health care registers
by: Cordtz, R, et al.
Published: (2018)

Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)
by: Fleischmann, R, et al.
Published: (2023)

Assessment of the many faces of PsA: single and composite measures in PsA clinical trials
by: McGagh, D, et al.
Published: (2020)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
by: Helliwell, PS, et al.
Published: (2022)

Quality of life improvements in patients with PsA who achieve remission or low disease activity targets: results from two clinical trials of ixekizumab at three years of treatment
by: Coates, LC, et al.
Published: (2021)

Treat-to-target in PsA: methods and necessity
by: Dures, E, et al.
Published: (2020)

PERI-operative biologic DMARD management: Stoppage or COntinuation during orthoPaEdic operations (the PERISCOPE trial) – a study protocol for a pragmatic, UK multicentre, superiority randomised controlled trial with an internal pilot, economic evaluation and nested qualitative study
by: Brady, S, et al.
Published: (2024)

Sex-specific challenges in patients with psoriatic arthritis (PsA): preliminary results from a systematic literature review (SLR)
by: Coates, LC, et al.
Published: (2021)

Screening/referral strategies for the early recognition of psoriatic arthritis (PsA) among patients with psoriasis: results of a GRAPPA survey
by: Song, K, et al.
Published: (2023)

Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study
by: Coates, LC, et al.
Published: (2021)

Content and face validity and feasibility of 5 candidate instruments for psoriatic arthritis randomized controlled trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting
by: Holland, R, et al.
Published: (2018)

What should be the primary target of ‘treat to target’ in PsA?
by: Coates, L, et al.
Published: (2018)

Usage of C-reactive protein testing in the diagnosis and monitoring of psoriatic arthritis (PsA): results from a real-world survey in the USA and Europe
by: Ogdie, A, et al.
Published: (2022)

Ethical issues in a TwiCs study in early PsA
by: Coates, L, et al.
Published: (2017)

Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritis—study protocol for the MONITOR-PsA study, a trials within cohorts study design
by: Rombach, I, et al.
Published: (2021)

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)
by: McInnes, IB, et al.
Published: (2023)

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1

Similar Items

Similar Items